Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones cng for polypeptides exhibiting murine interleukin-2 activity. One of these polypeptides is 168 amino acids in length, including a potential leader sequence of about 19 amino acids. The cDNA is derived from messenger RNA isolated from a mouse T-cell line after activation with concanavalin A. The cDNA was cloned by incorporation into a plasmid vector, which is then transformed into E. coli. The plasmid vector also contained DNA segments from the SV40 virus, permitting expression of the cDNA after transfection into a mammalian host cell, such as monkey COS-7 cells.

Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting mammalian IgE binding factor activity. One of these clones contains an open reading frame consisting of 556 codons. The cDNA is derived from messenger RNA isolated from a rat/mouse T-cell hybridoma line. The cDNA was cloned by incorporation into a pcD plasmid vector. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA to form a polypeptide having IgE potentiating activity after transfection into a mammalian host cell, such as monkey Cos7 cells.

Abstract: Immunosuppressive peptides having glycosylation inhibiting factor activity are provided.

Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting mammalian multi-lineage growth cell activity. One of these polypeptides is 166 amino acids in length, including a potential leader sequence of about 19 amino acids. The cDNA is derived from messenger RNA isolated from a mouse T-cell line after activation with concanavalin A. The cDNA was cloned by incorporation into a plasmid vector, which was then transformed into E. coli. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA after transfection into a mammalian host cell, such as monkey COS-7 cells.

Abstract: A hybridoma for production of monoclonal antibodies specific for mouse interleukin-2, but which antibodies do not significantly cross-react with human or rat interleukin-2. The hybridoma is a fusion product of a mouse myeloma cell line and from a rat immunized with supernatant from a mouse T cell line.

Abstract: Proteinaceous binding compositions are prepared employing hybrid DNA techogy, where the variable region polypeptides of immunoglobulins are substantially reproduced to provide relatively small protein molecules having binding specificity and lacking the undesirable aspects of the heavy regions of immunoglobulins. The compositions find a wide range of use, particularly for physiological purposes for diagnosis and therapy. The binding compositions may be modified by labeling with radioisotopes, fluorescers, and toxins for specific applications in diagnosis or therapy.